Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RL 315535

Drug Profile

RL 315535

Alternative Names: LY 315535

Latest Information Update: 16 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Shire Pharmaceuticals Group
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Muscarinic receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 21 Jun 2000 RL 315535 is available for licensing (http://www.shire.com)
  • 27 Mar 2000 Discontinued-I for Irritable bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top